We aimed to establish a benchmark for outcomes in elderly CLL patients treated before the availability of BCR-targeted therapies to help in properly positioning newer agents in the elderly CLL treatment paradigm. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.